- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04828785
Food As MedicinE for Diabetes (FAME-D)
Food is Medicine: A Randomized Clinical Trial of Medically Tailored Meals For Individuals With Type 2 Diabetes Mellitus and Food Insecurity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Food insecurity, "lack of access to enough food for an active, healthy life", affects over 20% of the 30 million Americans with diabetes. Food insecurity is more common in racial/ethnic minorities and those with lower socioeconomic status. Moreover, food insecurity is associated with worse diabetes control and increased complications, even after adjusting for other risk factors. Food insecurity is a major contributor to disparities in diabetes outcomes.
Medically tailored meal (MTM) delivery programs are a promising intervention for individuals with diabetes and food insecurity. MTM programs deliver fully prepared food, tailored by a registered dietitian nutritionist to the specific medical needs of the individual, and provide education to help optimize disease self-management. Food insecurity is typically addressed with food subsidies-offering additional financial resources that can be spent on food. While both food subsidies and MTM can increase healthy food access, MTM can help overcome other barriers to diabetes management including lack of time, ability, knowledge, and skills needed to prepare appropriate meals. The use of these programs is often called 'food as medicine', as the purpose is to provide exactly the foods needed to help prevent diabetes complications. MTM are receiving increasing public attention, but there are, as of yet, no full-scale trials to test its effects on diabetes outcomes when compared with other food insecurity interventions.
Our research team has developed a medically tailored meal intervention that combines provision of healthy food, tailored to the specific nutrition needs of the individual, with an evidence-based lifestyle intervention that uses the period of meal delivery as springboard to improve diabetes self-management, both while receiving meals and after meal delivery is completed.
This study is an explanatory-focused randomized trial to assess a community-based medically tailored meals intervention (n=200). It will be conducted among diverse participants referred for medically tailored meals. Adults with type 2 diabetes, Hemoglobin A1c between 7.0% and 12.0%, and BMI ≥ 25 kg/m2 (≥ 23 kg/m2 for those with Asian ancestry) will be enrolled and randomly assigned to intervention or usual care + food subsidy. The intervention group will receive meal delivery and its attendant lifestyle intervention for 6 months, while the usual care + food subsidy group will receive a $40/month food subsidy, along with usual diabetes care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of Type 2 Diabetes Mellitus
- Hemoglobin A1c ≥ 7.0% and ≤ 12.0% in last 12 months
- Experiencing food insecurity as indicated by 2-item Hunger Vital Sign
- English speaking
- BMI ≥25 kg/m^2 (≥ 23 kg/m^2 if self-report Asian ancestry)
- No plans to move from the area for at least 1 year
- Free living to the extent that participant has control over dietary intake
- Willing and able to provide written informed consent and participate in all study activities
Exclusion Criteria:
- Participant in diabetes, nutrition, or weight research intervention in last 12 months
- Another family member or household member is a study participant. Only one member of each household may take part in this study.
- Considering bariatric surgery in the next year or prior bariatric surgery in the past 2 years
- Lack of safe, stable residence and ability to store meals
- Lack of telephone
- Pregnancy/breastfeeding or intended pregnancy in the next year
- History of malignancy, other than non-melanoma skin cancer, unless surgically or medically cured > 5 years ago or in remission. Patients with localized prostate and breast cancer diagnosed during the course of routine screening will not be excluded.
- Advanced kidney disease (estimated creatinine clearance < 30 mL/min)
- Known drug or alcohol misuse in the past 2 years
- Known psychosis or major psychiatric illness that prevents participation with study activities
- Intermittent use of medications (e.g., oral or intravenous glucocorticoids) that are likely to affect blood sugar
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Medically Tailored Meal (MTM)
The Medically Tailored Meal (MTM) intervention consists of weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
|
weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
|
|
Active Comparator: Food Subsidy
As a comparison group, those not randomized to receive the MTM intervention will receive usual care provided by their clinicians not associated with the study, plus a food subsidy ($40/month) for 6 months, along with healthy eating information to guide use of that subsidy.
|
$40/month food subsidy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemoglobin A1c at Month 6
Time Frame: 6 months
|
Hemoglobin A1c Level
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemoglobin A1c at Month 12
Time Frame: 12 months
|
Hemoglobin A1c Level
|
12 months
|
|
Food Insecurity Score at Month 6
Time Frame: 6 months
|
Food Insecurity Score.
Score ranges from 0-10, with higher scores indicating greater food insecurity.
|
6 months
|
|
Food Insecurity Score at Month 12
Time Frame: 12 months
|
Food Insecurity Score.
Score ranges from 0-10, with higher scores indicating greater food insecurity.
|
12 months
|
|
Depressive Symptom Score at Month 6
Time Frame: 6 months
|
Depressive Symptoms as assessed by PROMIS SF (Short Form) v1.0 - Depression 4a.
Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US.
A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms.
|
6 months
|
|
Depressive Symptom Score at Month 12
Time Frame: 12 months
|
Depressive Symptoms as assessed by PROMIS SF v1.0 - Depression 4a.
Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US.
A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms.
|
12 months
|
|
Health-Related Quality of Life Score as Assessed by PROMIS (Patient-Reported Outcomes Measurement Information System)-29 at Month 6
Time Frame: 6 months
|
The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity).
Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US.
A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms.
These scores are then used to calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)).
|
6 months
|
|
Health-Related Quality of Life Score as Assessed by PROMIS-29 at Month 12
Time Frame: 12 months
|
The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity).
Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US.
A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms.
These scores are then used to calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)).
|
12 months
|
|
Diabetes Distress Score as Assessed by PAID (Problem Areas in Diabetes)-11 at Month 6
Time Frame: 6 months
|
Score ranges from 11-55 with higher scores indicating greater diabetes distress
|
6 months
|
|
Diabetes Distress Score as Assessed by PAID-11 at Month 12
Time Frame: 12 months
|
Score ranges from 11-55 with higher scores indicating greater diabetes distress
|
12 months
|
|
Number of Participants With Self-reported Hypoglycemia at Month 6
Time Frame: 6 months
|
Reported hypoglycemia between 0 and 6 months after randomization
|
6 months
|
|
Number of Participants With Self-reported Hypoglycemia at Month 12
Time Frame: 12 months
|
Reported hypoglycemia between 6 and 12 months after randomization
|
12 months
|
|
Number of Participants With Self-reported Severe Hypoglycemia at Month 6
Time Frame: 6 months
|
Reported severe hypoglycemia between 0 and 6 months after randomization
|
6 months
|
|
Number of Participants With Self-reported Severe Hypoglycemia at Month 12
Time Frame: 12 months
|
Reported severe hypoglycemia between 6 and 12 months after randomization
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bodyweight at Month 6
Time Frame: 6 months
|
Bodyweight measured in Kg
|
6 months
|
|
Bodyweight at Month 12
Time Frame: 12 months
|
Bodyweight measured in Kg
|
12 months
|
|
Systolic Blood Pressure at Month 6
Time Frame: 6 months
|
Systolic blood pressure in mm Hg
|
6 months
|
|
Systolic Blood Pressure at Month 12
Time Frame: 12 months
|
Systolic blood pressure in mm Hg
|
12 months
|
|
Diastolic Blood Pressure at Month 6
Time Frame: 6 months
|
Diastolic blood pressure measured in mm Hg
|
6 months
|
|
Diastolic Blood Pressure at Month 12
Time Frame: 12 months
|
Diastolic blood pressure in mm Hg
|
12 months
|
|
ARMS-D (Adherence to Refills and Medications Scale-Diabetes) Medication Adherence Score at Month 6
Time Frame: 6 months
|
Medication Adherence as assessed by 7-item ARMS-D scale.
Scores range from 7 to 28, with higher scores indicating more problems with adherence.
|
6 months
|
|
ARMS-D Medication Adherence Score at Month 12
Time Frame: 12 months
|
Medication Adherence as assessed by 7-item ARMS-D scale.
Scores range from 7 to 28, with higher scores indicating more problems with adherence.
|
12 months
|
|
Diabetes Self-Care Activities Medication Adherence Score at Month 6
Time Frame: 6 months
|
Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure.
Scores range from 0-7 with higher scores indicating better adherence.
|
6 months
|
|
Diabetes Self-Care Activities Medication Adherence Score at Month 12
Time Frame: 12 months
|
Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure.
Scores range from 0-7 with higher scores indicating better adherence.
|
12 months
|
|
Food/Medication Trade-offs at Month 6
Time Frame: 6 months
|
Single item-indicators of trading off medication for food or food for medication.
An affirmative response indicates the presence of a trade-off.
|
6 months
|
|
Food/Medication Trade-offs at Month 12
Time Frame: 12 months
|
Single item-indicators of trading off medication for food or food for medication.
An affirmative response indicates the presence of a trade-off.
|
12 months
|
|
Housing Insecurity at Month 6
Time Frame: 6 months
|
Self-report of being worried about losing housing
|
6 months
|
|
Housing Insecurity Score at Month 12
Time Frame: 12 months
|
Self-report of being worried about losing housing
|
12 months
|
|
Transportation Barriers at Month 6
Time Frame: 6 months
|
Self-report of transportation barriers to attending medical appointments
|
6 months
|
|
Transportation Barriers at Month 12
Time Frame: 12 months
|
Self-report of transportation barriers to attending medical appointments
|
12 months
|
|
Financial Strain
Time Frame: 6 months
|
Self-report of financial strain
|
6 months
|
|
Financial Strain
Time Frame: 12 months
|
Self-report of financial strain
|
12 months
|
|
Care Delay at Month 6
Time Frame: 6 months
|
Self-report of delaying healthcare due to cost
|
6 months
|
|
Care Delay at Month 12
Time Frame: 12 months
|
Self-report of delaying healthcare due to cost
|
12 months
|
|
Diet Self-Efficacy Score at Month 6
Time Frame: 6 months
|
Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale.
Scores range from 16 to 80 with higher scores indicating greater self-efficacy.
|
6 months
|
|
Diet Self-Efficacy Score at Month 12
Time Frame: 12 months
|
Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale.
Scores range from 16 to 80 with higher scores indicating greater self-efficacy.
|
12 months
|
|
Perceived Diabetes Self-Management Self-Efficacy Score at Month 6
Time Frame: 6 months
|
Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale.
Scores range from 8 to 40 with higher scores indicating greater self-efficacy
|
6 months
|
|
Perceived Diabetes Self-Management Self-Efficacy Score at Month 12
Time Frame: 12 months
|
Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale.
Scores range from 8 to 40 with higher scores indicating greater self-efficacy
|
12 months
|
|
Diet Quality Score at Month 6
Time Frame: 6 months
|
Diet Quality as assessed by Brief Dietary Assessment Scale.
The total score (range 0-50) is reported (higher score indicates better diet quality).
The total score is comprised of 3 sections (or subscales) used to assess dietary patterns.
The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10).
Total score equals the sum of the 3 subscales.
|
6 months
|
|
Diet Quality Score at Month 12
Time Frame: 12 months
|
Diet Quality as assessed by Brief Dietary Assessment Scale.
The total score (range 0-50) is reported (higher score indicates better diet quality).
The total score is comprised of 3 sections (or subscales) used to assess dietary patterns.
The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10).
Total score equals the sum of the 3 subscales.
|
12 months
|
|
Probability of Cost-Related Medication Underuse at Month 6
Time Frame: 6 months
|
Any affirmative response to one or more of four cost-related medication underuse items derived from the Medical Expenditure Panel Survey.
These items ask about not filling a prescription due to cost; skipping medication doses to save money; taking less medication than prescribed to save money; or 4) delaying filling a prescription to save money.
Participants with ≥1 affirmative response were classified as having Cost-Related Medication Underuse (CRMU), and the reported values represent the estimated probability of CRMU.
|
6 months
|
|
Probability of Cost-Related Medication Underuse at Month 12
Time Frame: 12 months
|
Any affirmative response to one or more of four cost-related medication underuse items derived from the Medical Expenditure Panel Survey.
These items ask about not filling a prescription due to cost; skipping medication doses to save money; taking less medication than prescribed to save money; or 4) delaying filling a prescription to save money.
Participants with ≥1 affirmative response were classified as having Cost-Related Medication Underuse (CRMU), and the reported values represent the estimated probability of CRMU.
|
12 months
|
|
Stress Score at 6 Months
Time Frame: 6 months
|
Stress as assessed by perceived stress scale.
Scores range from 0 to 40 with higher scores indicating higher perceived stress.
|
6 months
|
|
Stress Score at 12 Months
Time Frame: 12 months
|
Stress as assessed by perceived stress scale.
Scores range from 0 to 40 with higher scores indicating higher perceived stress.
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Seth Berkowitz, MD, UNC
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-2847
- R01DK125831 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.